Brain Wealthy
    What's Hot

    Bridging the Gender Gap: Inspiring Words from the Women Making Waves on Starship | Annie Handrick | | Starship Technologies | March 2023

    March 8, 2023

    AI apps like ChatGPT may finally kill the cover letter

    March 8, 2023

    Snow Crash author Neal Stephenson on the metaverse, making movies, climate fears

    March 6, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»Azafaros Receives FDA IND Clearance and Fast Track Designation for Lead Asset AZ-3102
    Neurology

    Azafaros Receives FDA IND Clearance and Fast Track Designation for Lead Asset AZ-3102

    brainwealthy_vws1exBy brainwealthy_vws1exJanuary 5, 2023No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Leiden, Netherlands–(business wire)– Azafaros BV today received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 clinical trial of AZ-3102, a lead asset for the treatment of GM2 announced that Gangliosidosis (GM2) and Niemann-Pick disease type C (NP-C). In addition to IND approval, the FDA granted AZ-3102 Fast Track designation for GM1 and GM2 gangliosidosis and NP-C investigations. Fast Track is a process designed to expedite the development and expedite review of medicines that treat serious conditions and meet unmet medical needs.1

    Azafaros’ RAINBOW Phase 2 Study is a Multinational, Double-Blind Study Investigating the Safety, Tolerability, and Pharmacokinetics of Once-Daily Oral AZ-3102 for 12 Weeks in GM2 and NP-C Patients , placebo-controlled, parallel-group trials. From 12 to 20 years old. This research is being conducted in other countries as well as the United States. The pharmacodynamics and effects of AZ-3102 on potential disease biomarkers will also be measured during the study. Professor Mark C. Patterson, MD, Professor of Neurology, Pediatrics, and Medical Genetics, Pediatric Neurology, Mayo Clinic, Rochester, Minnesota, is the principal investigator for the US portion of the study.

    “GM2 gangliosidosis and Niemann-Pick disease type C are debilitating and life-threatening diseases that have a devastating impact on patients and their families, and new treatment options are urgently needed.” AZ-3102 has unique characteristics that make it potentially an effective and innovative treatment for these patients.” Professor Patterson.

    Stefano Portolano, MD, CEO of Azafaros, added: We look forward to furthering our Phase 2 study and initiating a pivotal Phase 3 study, marking two important milestones in providing a new treatment option for patients with severe and rare genetic diseases. looking forward to ”

    About AZ-3102

    AZ-3102 is a therapeutic candidate developed for people with lysosomal storage diseases (LSD) with neurological involvement. AZ-3102 is an orally available, brain-penetrating azasaccharide designed with a unique dual mechanism of action by inhibiting two key enzymes that regulate glycosphingolipid metabolism.

    In 2022, the compound received Fast Track Designation for GM1 and GM2 gangliosidosis, Niemann-Pick disease type C (NP-C), GM2 gangliosidosis (Sandhoff and Tay-Sachs disease) and C. from NP- FDA

    About lysosomal storage diseases

    Lysosomal storage diseases are a group of over 70 diseases characterized by lysosomal dysfunction, most of which are inherited as autosomal recessive traits. These disorders are individually rare, but collectively affect her 1 in 5,000 live births. They usually begin in infancy and childhood, but adult-onset forms also occur.

    They are caused by genetic mutations that affect the function of certain enzymes, transporters, receptors, or hormones involved in the metabolism and transport of body components such as sugars, proteins, and lipids.

    These malfunctions can impair the assembly of important metabolic end products required for normal functioning of the body, or lead to harmful accumulation of intermediate metabolites.

    GM1 and GM2 gangliosidosis (Tay-Sachs and Sandhoff disease), Niemann-Pick, Krabbe, Farber, Fabry, and Gaucher disease are examples of lysosomal lipid storage disorders.

    GM1 and GM2 gangliosidosis (Tay-Sachs disease and Sandhoff disease) are caused by accumulation of GM1 or GM2 gangliosides in the central nervous system (CNS), respectively, and are associated with progressive and severe neurological disability and early death. Brings These diseases primarily affect infants and children, and no disease-modifying treatments are currently available.

    Niemann-Pick disease type C (NP-C) is a progressive, life-limiting neurological condition caused by mutations in the NPC1 or NPC2 genes and aberrant endosomal-lysosomal trafficking, and is associated with a variety of ganglioside-containing disorders in the CNS. Causes lipid accumulation. Disease onset occurs throughout the life of the affected individual, from prenatal to adulthood. The focus of treatment is symptom management.

    About Azaphalos

    Azafaros is a clinical-stage company founded in 2018, led by a team of experienced industry experts with a deep understanding of the mechanisms of rare genetic diseases, the compound library of Leiden University. Azafaros aims to build a pipeline of disease-modifying therapies to provide new treatment options for patients and their families. The Company’s lead clinical-stage programs are GM1 and GM2 gangliosidosis (Tay-Sachs and Sandhoff disease) and Niemann-Pick disease type C (NP-C). Azafaros’ team leverages its know-how, network and courage to challenge traditional development paths and bring new medicines to patients with rare diseases in need faster. Azafaros is backed by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures, BioMedPartners and Schroder Capital.

    ———–

    1 https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous Article“I couldn’t imagine how he could be so insensitive.”
    Next Article Australian state launches first multicultural mental health hotline
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.